Intended for the following indications:
·Prevention of skeletal related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with advanced malignancies involving bone.
·Treatment of adults and skeletally mature adolescents with giant cell tumour of bone that is unresectable or where surgical resection is likely to result in severe morbidity.
NOVACTAM is indicated for the treatment of infections due to susceptible strains of the designated microorganisms in the conditions listed below.
Skin and Skin Structure Infections caused by beta‑lactamase producing strains of Staphylococcus aureus, Escherichia coli,* Klebsiella spp.* (including K. pneumoniae*), Proteus mirabilis,* Bacteroides fragilis,* Enterobacter spp.,* and Acinetobacter calcoaceticus.*
Intra‑Abdominal Infections caused by beta‑lactamase producing strains of Escherichia coli, Klebsiella spp. (including K. pneumoniae*), Bacteroides spp. (including B. fragilis), and Enterobacter spp.*
Gynecological Infections caused by beta‑lactamase producing strains of Escherichia coli,* and Bacteroides spp.* (including B. fragilis*).
* Efficacy for this organism in this organ system was studied in fewer than 10 infections.
While NOVACTAM is indicated only for the conditions listed above, infections caused by ampicillin‑susceptible organisms are also amenable to treatment with NOVACTAM due to its ampicillin content. Therefore, mixed infections caused by ampicillin‑susceptible organisms and beta‑lactamase producing organisms susceptible to NOVACTAM should not require the addition of another antibacterial.
Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify the organisms causing infection and to determine their susceptibility to NOVACTAM.
This medicinal product is for diagnostic use.
Ultravist-240, -300, -370:
–Angiography, angiocardiography, digital subtraction angiography
–Contrast enhancement in computerised tomography
–Urography
–Visualization of body cavities
(Exception: myelography, ventriculography, cisternography)
Ultravist-300/-370:
Used in adult women for contrast-enhanced mammography to assess and detect known or suspicious lesions of the breast,
–in addition to mammography (with or without ultrasound) or
–as an alternative to magnetic resonance imaging (MRI) if MRI is contraindicated or not available.
Renal Tubular Acidosis (RTA) with Calcium Stones
Potassium citrate is indicated for the management of renal tubular acidosis.
Hypocitraturic Calcium Oxalate Nephrolithiasis of any Etiology
Potassium citrate is indicated for the management of Hypocitraturic calcium oxalate nephrolithiasis.
Uric Acid Lithiasis with or without Calcium Stones
Potassium citrate is indicated for the management of uric acid lithiasis with or without calcium stones.
a) the control of hypertension;
b) the management of angina pectoris;
c) long term management against re-infarction after recovery from acute myocardial infarction;
d) the control of most forms of cardiac dysrhythmias;
e) the prophylaxis of migraine;
f) the management of essential tremor;
g) relief of situational anxiety and generalised anxiety symptoms, particularly those of somatic type;
h) prophylaxis of upper gastrointestinal bleeding in patients with portal hypertension and oesophageal varices;
i) the adjunctive management of thyrotoxicosis and thyrotoxic crisis;
j) management of hypertrophic obstructive cardiomyopathy;
k) management of phaeochromocytoma peri-operatively (with an alpha-blocker).
Gatifloxacin is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms:
• Aerobic gram-positive bacteria: Staphylococcus aureus Staphylococcus epidermidis Streptococcus mitis group* Streptococcus oralis* Streptococcus pneumoniae
• Aerobic gram-negative bacteria: Haemophilus influenzae
*Efficacy for these organisms were studied in fewer than 10 infections.
Sirolimus is indicated for the prophylaxis of organ rejection in adult patients at low to moderate immunological risk receiving a renal transplant. It is recommended that Sirolimus be used initially in combination with ciclosporin microemulsion and corticosteroids for 2 to 3 months. Sirolimus may be continued as maintenance therapy with corticosteroids only if ciclosporin microemulsion can be progressively discontinued
Sirolimus is indicated for the prophylaxis of organ rejection in adult patients at low to moderate immunological risk receiving a renal transplant. It is recommended that Sirolimus be used initially in combination with ciclosporin microemulsion and corticosteroids for 2 to 3 months. Sirolimus may be continued as maintenance therapy with corticosteroids only if ciclosporin microemulsion can be progressively discontinued
